Multicenter, Open-label, Safety and Tolerability Study

Inclusion Criteria:

1. Subjects who participated in 331-07-203 and who, in the opinion of the investigator,
have the potential to benefit from continued administration of OPC-34712 for the
treatment of schizophrenia.

2. Outpatient status at last visit of Study 331-07-203.

Exclusion Criteria:

1. Sexually active males who are not practicing two different methods of birth control
during the study and for 90 days after the last dose of study medication or who will
not remain abstinent during the study and for 90 days after the last dose, or
sexually active females of childbearing potential who are not practicing two
different methods of birth control during the study and for 30 days after the last
dose of study medication or who will not remain abstinent during the study and for 30
days after the last dose. If employing birth control, two of the following
precautions must be used: vasectomy, tubal ligation, vaginal diaphragm, intrauterine
device, birth control pill, birth control depot injection, birth control implant,
condom, or sponge with spermicide.

2. Females who are breast-feeding and/or who have a positive pregnancy test result prior
to receiving open-label OPC-34712.

3. Subjects who during the course of their participation in 331-07-203 were treated in
violation of the protocol or who developed ANY exclusion criteria during the course
of their participation.

4. Subjects who do not continue to meet all applicable inclusion/exclusion criteria for
Protocol 331-07-203 at the last visit (ie, Week 6) of Protocol 331-07-203.

5. Subjects who represent a risk of committing suicide based on an answer of "Yes" to
either Question 4 (Active Suicidal Ideation with Some Intent to Act, Without Specific
Plan) or Question 5 (Active Suicidal Ideation with Specific Plan and Intent) on the
"Suicidal Ideation" portion of the C-SSRS, or an answer of "Yes" to any of the
suicide-related behaviors (actual attempt, interrupted attempt, aborted attempt,
preparatory acts or behavior) on the "Suicidal Behavior" portion of the C-SSRS. A
subject who has had any suicidal ideation within the last 6 months, any suicidal
behaviors within the last two years, or who in the clinical judgment of the
investigator presents a serious risk of suicide should be excluded from the study.

6. Subjects who would be likely to require prohibited concomitant therapy during the
study.

7. Any subject who, in the opinion of the investigator, should not participate in the
study.